The O22 trial's positive result for adjuvant Pembrolizumab plus Belzutafan was unexpected, as experts believed kidney cancer recurrence was primarily immune-driven, not HIF-driven. This outcome forces a re-evaluation of the underlying biology of recurrence and suggests a significant role for HIF inhibition in the adjuvant setting.

Despite initial preclinical concerns that HIF-2 inhibition might dampen immune response, the success of the Pembro+Belzutifan combination is likely due to the simple additive effect of two active drugs. Newer data refutes the immune-dampening theory, showing no negative impact on the tumor microenvironment and possibly even a reduction in immunosuppressive cells.

In renal cell carcinoma, Arcus's casdadafin demonstrated a 12.2-month median PFS as a monotherapy. This nearly matches the 13.7-month PFS of Merck's competitor drug, belzutafan, when used in combination. This suggests Arcus's upcoming combination data could be substantially superior.

The LITESPARK 011 trial showed the Lenvatinib/Belzutifan combination doubled the duration of response compared to Cabozantinib. This durability, with some patients in remission for over three years, is considered a more significant clinical advance than the modest increase in overall response rate, representing a key differentiator for the regimen.

Despite Belzutafan's clinical successes, effective biomarkers for patient selection are almost non-existent. Experts anticipate a significant increase in understanding over the next 12-24 months from correlative studies, which will likely reveal novel gene expression and tissue-based markers beyond obvious candidates like serum EPO.

Previous adjuvant trials in kidney cancer using more toxic VEGF-TKIs largely failed. Belzutifan's success suggests that in the adjuvant setting, a drug's tolerability and the ability for patients to maintain dose intensity are more critical for efficacy than raw potency in advanced disease. TKIs were often too toxic for patients to endure for a full year.

The O11 trial (Len-Belzutafan vs. Cabozantinib) presents the first randomized Phase 3 data for a VEGF/HIF inhibitor combination. Its results will be pivotal in determining if this more toxic doublet approach is justified over monotherapy for IO-refractory kidney cancer, weighing the magnitude of benefit against increased side effects.

The progression-free survival (PFS) curves for Belzutifan regimens consistently overlap with controls for 6-8 months before separating. This signature “Belzutifan effect,” seen across multiple trials, suggests the drug provides durable, long-term disease control for a subset of patients rather than immediate, broad efficacy, hinting at a distinct biological mechanism.

Unlike VEGF TKIs that primarily target the tumor vasculature, the HIF-2 inhibitor belzutifan has a direct anti-tumor cell effect. This mechanism may be uniquely effective against micrometastatic disease, following the logic of traditional chemotherapy. This distinction could explain its surprising success in the adjuvant setting where multiple VEGF TKIs have failed.